EORTC 1740: Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508853-13-00

Acronym

EORTC 1740-HNCG

Enrollment

Registered

2024-03-21

Start date

2019-10-31

Completion date

Unknown

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oropharyngeal Squamous Cell Carcinoma

Brief summary

Event-free survival (EFS)

Detailed description

Overall survival (OS), Loco Regional Control (LRC), Distant Metastasis Free Survival (DMFS), Toxicity, Quality of life

Interventions

DRUGCISPLATIN

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Event-free survival (EFS)	—

Secondary

Measure	Time frame
Overall survival (OS), Loco Regional Control (LRC), Distant Metastasis Free Survival (DMFS), Toxicity, Quality of life	—

Countries

Belgium, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026